United States Endometrial Cancer Market By Type of Cancer (Endometrial Carcinoma, Uterine Sarcomas), By Type of Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, Other Types of Therapies), By Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, Other Diagnosis Methods), By Region, Competition Forecast & Opportunities, 2028
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited States Endometrial Cancer Market By Type of Cancer (Endometrial Carcinoma, Uterine Sarcomas), By Type of Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, Other Types of Therapies), By Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, Other Diagnosis Methods), By Region, Competition Forecast & Opportunities, 2028
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 1.09 billion |
| CAGR (2023-2028) | 8.06% |
| Fastest Growing Segment | Biopsy |
| Largest Market | Mid-West |
Market Overview
Key Market Drivers
Rising Cases of Endometrial cancer
Increased Advances in Early Detection
Rising Minimally Invasive Surgical Techniques
Increasing Clinical Trials and Research
Key Market Challenges
High Treatment Costs
Limited Treatment Options
Rising Incidence Rates
Key Market Trends
Advances in Precision Medicine
Immunotherapy Breakthroughs
Segmental Insights
Type of Therapy Insights
In 2022, the Endometrial Cancer Market was dominated by the chemotherapy segment and is predicted to continue expanding over the coming years.
Type of Cancer Insights
In 2022, the Endometrial Cancer Market was dominated by the Endometrial Carcinoma segment and is predicted to continue expanding over the coming years.
Regional Insights
In 2022, the United States Endometrial Cancer Market was dominated by the Mid-West segment and is predicted to continue expanding over the coming years.
Recent Development
- The United States Food and DrugAdministration (FDA) authorised KEYTRUDA, a Merck anti-PD-1 therapy, as asingle agent in March 2022 for the treatment of patients with advancedendometrial carcinoma that is identified by an FDA-approved test as having microsatelliteinstability-high (MSI-H) or mismatch repair deficient (dMMR) levels. Theseindividuals were not candidates for curative surgery or radiotherapy becausetheir disease had progressed after earlier systemic therapy in any setting.
- In November 2021, the Americanmultinational pharmaceutical company Merck & Co., Inc. and the Japanesepharmaceutical company Eisai Co., Ltd. received approval from the EuropeanCommission to combine LENVIMA, an orally available multiple receptor tyrosinekinase inhibitor, with KEYTRUDA, an anti-PD-1 therapy, in the treatment ofprogressive or recurrent endometrial carcinoma in adults who have conditionprogression on or after prior treatment.
Key Market Players
- Merck KGaA
- Eisai Co. Ltd
- Novartis AG
- Elekta AB
- Siemens Healthineers (Varian MedicalSystems, Inc.)
- GSK plc
- Karyopharm Therapeutics
- Takeda Pharmaceutical Company Limited
- Bristol Myers Squibb
- F. Hoffmann-La Roche AG
| By Type of Cancer | By Type of Therapy | By Diagnosis Method | By Region |
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy